Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on April 29th, 2025 | 07:10 CEST
Gold rush 2.0: Desert Gold could become the next takeover target in West Africa
In uncertain times, gold is again gaining attention as a safe haven. While the price of gold continues to climb to new record highs, exploration companies with substantial resources offer attractive potential – especially in established gold regions such as West Africa. Desert Gold Ventures, a Canadian gold explorer, is well positioned here. With a 440 sq km project in Mali, surrounded by large producing mines, and already confirmed and inferred resources of around 1.1 million ounces, the Company could emerge as a surprise candidate. But what makes Desert Gold special? We take a look at the facts.
Read
Commented by Armin Schulz on April 28th, 2025 | 07:10 CEST
BYD doubles profits, European Lithium unlocks Greenland's treasures – can Volkswagen still keep up?
The global automotive industry is in turmoil. While the US is trying to seal off the market with drastic tariffs, Europe is seeking to reduce its dependence on raw materials. Lithium – the "white gold" of e-mobility – is becoming the key to technological sovereignty. That is why 47 projects in 13 member states are being funded. But can European manufacturers break their dependence on China while trade conflicts tear supply chains apart? And who stands to gain when protectionism meets innovation? BYD aims to expand westward. European Lithium seeks to mine the raw material in Austria. Volkswagen is struggling with US tariffs and trying to maintain its market share in China. The Financial Times recently reported that Donald Trump wants to accommodate automakers on tariffs.
Read
Commented by Armin Schulz on April 24th, 2025 | 07:00 CEST
Almonty Industries - Trade restrictions are not always a bad thing; they can also represent a real opportunity
Trade restrictions, particularly China's recent export restrictions on critical metals and rare earths, have put pressure on the global economy. According to a report by Reuters, China has warned South Korean companies against supplying products containing Chinese rare earth minerals to US defense companies. However, these developments open up opportunities for Western companies like Almonty Industries to strengthen their security of supply and position themselves as reliable partners in critical supply chains. Investors looking for long-term, stable investment options, in particular, should take a closer look at the potential of Almonty Industries.
Read
Commented by Armin Schulz on April 22nd, 2025 | 07:30 CEST
Mobility and logistics under pressure: BYD, dynaCERT, and Daimler Truck put to the innovation test
The transport industry is at a crossroads: With CO2 limits getting stricter and supply chains needing to be smarter than ever, companies are struggling to find the right balance between efficiency and sustainability. According to the "NEW MOBILITY REPORT 2025," the battle for dominance in tomorrow's logistics is underway – driven by electric trucks, AI-managed fleets, and hydrogen prototypes. But in the race to be the frontrunner, three key players are pulling different levers. BYD focuses on innovative all-electric passenger vehicles, dynaCERT offers disruptive retrofit solutions for diesel engines, and Daimler Truck aims to combine autonomous systems with green drives. Who is driving the revolution – and where will investors benefit the most?
Read
Commented by Armin Schulz on April 17th, 2025 | 08:10 CEST
Blockbuster or takeover fever? Why Novo Nordisk, Defence Therapeutics, and Pfizer are now attracting attention
The biotech and pharmaceutical industry resembles a billion-dollar chessboard! A single move – whether a takeover or drug approval – can double share prices in a matter of hours or completely reshape entire markets. While investors are still marveling at the spectacular rally of Theratechnologies, which opened with a gap up and then soared another 45% in a single day, or analyzing the Phase-3 explosion at Corcept, the next players are already lining up for the big coup. Because in this arena, it is not just about who develops the next blockbuster but also who buys, sells, or forms strategic alliances. There are three names to have on your radar: Novo Nordisk, Defence Therapeutics, and Pfizer. Each of these companies is pursuing its own master plan.
Read
Commented by Armin Schulz on April 14th, 2025 | 07:20 CEST
123fahrschule is booming, while Volkswagen and Mercedes-Benz are struggling with tariffs and e-mobility
The German automotive industry is struggling with punitive tariffs and declining competitiveness, while the driving school sector is booming – a paradox of future markets. As Volkswagen and Mercedes-Benz face export declines and try to integrate the electric revolution into their existing structures, 123fahrschule is focusing on digital learning concepts and sustainability. But what connects luxury automakers with driving schools? Both face the question of how to master technology, global crises, and younger target groups. Innovation requires more than horsepower and premium labels. We look at how 123fahrschule, Volkswagen, and Mercedes-Benz meet these challenges and aim to shape the future.
Read
Commented by Armin Schulz on April 14th, 2025 | 06:50 CEST
Gold shines as a safe haven – Tocvan Ventures sets new standards with its Mexico project
With a gold price above USD 3,100 per ounce, the precious metal remains a stable anchor in uncertain times. For investors seeking to profit disproportionately from this dynamic, exploration companies with promising projects are coming into focus. One of the most exciting players is Tocvan Ventures, which recently presented spectacular drilling results from its Gran Pilar project in Sonora, Mexico. The Company is strategically well-positioned to benefit from the increasing demand for gold and silver – and is now offering investors an attractive entry scenario.
Read
Commented by Armin Schulz on April 9th, 2025 | 07:00 CEST
From diabetes to cancer: How Novo Nordisk, NetraMark, and BioNTech are reinventing medicine
The medicine of tomorrow is being written today – with algorithms that personalize therapies, mRNA vaccines that fight cancer, and drugs that conquer chronic diseases. While AI is revolutionizing clinical trials and shifting billion-dollar markets, biotech pioneers are fighting for dominance in precision medicine. Who is driving this transformation? Three companies are in the spotlight: Novo Nordisk, a pioneer in the fight against diabetes and obesity; NetraMark, whose AI is decoding clinical trials; and BioNTech, which is redefining oncology with mRNA. Their innovations are not just dreams of the future – they are already changing how lives are saved and extended.
Read
Commented by Armin Schulz on April 8th, 2025 | 07:30 CEST
Bayer, BioNxt Solutions, Evotec – False tariff alarm for pharma and biotech! Which stocks are worth buying?
The provisional exemption from tariffs for medicines and pharmaceutical products offers the industry a breather – but appearances are deceptive. Based on WTO rules, the exemptions protect German exports in the multi-billion-dollar US market. However, indirect risks lurk in the form of rising costs for raw materials, political unpredictability, and dependence on global supply chains. While the sector can breathe a sigh of relief in the short term, long-term trade conflicts are forcing strategic maneuvering. For Bayer, the US market is very important. BioNxt Solutions is developing disruptive drug delivery solutions, and Evotec aims to redefine drug discovery with artificial intelligence. Let's take a closer look at these three companies.
Read
Commented by Armin Schulz on April 8th, 2025 | 07:10 CEST
Palantir US-Tech stocks plummet – MiMedia defies the storm, Xiaomi makes strategic decisions
The global financial markets are undergoing an unprecedented stress test. The latest tariff measures by the Trump administration have ignited a trade conflict that is putting technology companies at the center of the turbulence. While US companies such as Apple and Nvidia are suffering from supply chain disruptions and plunging share prices, the technology sector is on the brink of a turning point. However, not all players are reacting in the same way. Palantir shares have recently plummeted, while MiMedia, a cloud specialist, is successfully focusing on disruptive business models – and Xiaomi is demonstrating resilience. In this environment, we take a closer look at the individual stocks.
Read